

PUBLIC SUMMARY DOCUMENT

Product: Coloplast Brava Protective Seal Convex

Applicant: Coloplast Pty Ltd

Date of SPAP Meeting: 12 October 2021

1. Proposed Listing on the Stoma Appliance Scheme

The applicant, Coloplast, sought listing of the Coloplast Brava Protective Seal Convex in subgroup 9(1) of the Stoma Appliance Scheme (the Scheme) Schedule. The product, including six variants, was proposed for listing at the unit price of \$4.531, with a maximum monthly quantity of 30 units.

2. Comparator

The applicant nominated Hollister Adapt CeraRings Convex (round and oval) (SAS Code 80139W) as the comparator. This product is currently listed in subgroup 9(1) of the Scheme Schedule at the unit price of \$4.531 with a maximum monthly quantity of 30 units. The Stoma Product Assessment Panel (SPAP) accepted this product as an appropriate comparator.

3. Background

This was the SPAP's first consideration of this product.

4. Clinical Place for the Product

The proposed product will provide an alternative for users requiring hydrocolloid seals.

5. SPAP Comment

Clinical Analysis

The Panel noted the proposed product is an extension of the existing Coloplast Brava Protective Seal range with the convex profile for ease of moulding to accommodate individual body shapes.

The Panel agreed the proposed product provides an alternative to what is currently listed in subgroup 9(1) of the Scheme Schedule.

Economic Analysis

Not undertaken.

Financial Analysis

It is therefore, unlikely that there would be any budgetary impact for the Scheme as a consequence of listing this product.

6. SPAP Recommendation

The SPAP recommended that the Coloplast Brava Protective Seal Convex, including six variants, be listed in subgroup 9(1) of the Scheme Schedule at the unit price of \$4.531, with a maximum monthly quantity of 30 units. on a cost minimisation basis compared to products currently listed in subgroup 9(1) of the Scheme Schedule.

7. Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

8. Applicant's Comment

Coloplast agrees with the SPAP's recommendation.